Serina Therapeutics Takes the Stage at Major Investment Event
Serina Therapeutics, Inc., also known as Serina (NYSE American: SER), is set to make an impactful presentation at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event unfolds in New York City, where Steve Ledger, the Chief Executive Officer of Serina, will take the spotlight at 9:30 a.m. ET. This opportunity reflects the company's continued commitment to advancing its cutting-edge drug optimization technology utilizing its proprietary POZ Platform.
Engaging Presentations and Webcasts
Registered attendees of the conference will have the privilege of joining a live webcast of Serina's presentation. In the fast-paced world of biotechnology, such platforms allow companies like Serina to share their latest innovations directly with potential investors, industry leaders, and stakeholders. Following the event, an archived replay will be available on-demand for 90 days, ensuring that anyone interested can access the insights shared during the conference.
About Serina Therapeutics
Serina is not just another name in the biotechnology landscape; it is a pioneering entity that is focused on addressing neurological diseases and a variety of other indications through a deep pipeline of drug candidates. The backbone of Serina’s approach is its proprietary POZ Platform™, which enhances the efficacy and safety of diverse therapeutic modalities. This unique platform's versatility includes applications in small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs), positioning Serina as a leader in innovative treatment solutions.
Strategic Location and Development Focus
Headquartered in Huntsville, Alabama, Serina occupies a strategic location that fosters collaboration with cutting-edge research facilitated by the HudsonAlpha Institute of Biotechnology. This partnership not only enhances their research capabilities but also places them at the forefront of technological advancements in the healthcare industry. As they continue to develop their drug candidates, the potential for creating impactful treatments is higher than ever.
Committed to Transparency and Progress
As part of a clinical-stage biotechnology company, Serina emphasizes its dedication to transparency regarding its research and development processes. Potential investors and partners are encouraged to stay informed about Serina's milestones through regular updates. This commitment not only aids in building trust with stakeholders but also provides valuable insights into the challenges and triumphs faced by the company on its journey to success.
Frequently Asked Questions
What is Serina Therapeutics known for?
Serina Therapeutics focuses on developing innovative drug candidates for treating neurological diseases utilizing their proprietary POZ Platform.
When will Serina present at the conference?
Steve Ledger will present Serina's innovations on September 8, 2025, at 9:30 a.m. ET during the H.C. Wainwright Global Investment Conference.
How can I view Serina's presentation?
Registered attendees can view a live webcast of the presentation, and there will be a replay available on demand for 90 days afterward.
Where is Serina headquartered?
Serina Therapeutics is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.
Who can I contact for more information about Serina?
For inquiries, you can contact Stefan Riley at (256) 327-9630 or email sriley@serinatherapeutics.com.
